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Parkinson’s disease (PD) is a progressive neurodegenerative disorder in which the major
pathologic substrate is a loss of dopaminergic neurons from the substantia nigra. Our
main objective was to determine the correspondence between changes in the substantia
nigra, evident in neuromelanin and iron sensitive magnetic resonance imaging (MRI),
and dopaminergic striatal innervation loss in patients with PD. Eighteen patients and
18 healthy control subjects were included in the study. Using neuromelanin-MRI, we
measured the volume of the substantia nigra and the contrast-to-noise-ratio between
substantia nigra and a background region. The apparent transverse relaxation rate
and magnetic susceptibility of the substantia nigra were calculated from dual-echo
MRI. Striatal dopaminergic innervation was measured as density of dopamine
transporter (DAT) by means of single-photon emission computed tomography and
[123I] N-ω-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) tropane. Patients showed a
reduced volume of the substantia nigra and contrast-to-noise-ratio and both positively
correlated with the corresponding striatal DAT density. The apparent transverse relaxation
rate and magnetic susceptibility values of the substantia nigra did not differ between
patients and healthy controls. The best predictor of DAT reduction was the volume of
the substantia nigra. Clinical and imaging correlations were also investigated for the
locus coeruleus. Our results suggest that neuromelanin-MRI can be used for quantifying
substantia nigra pathology in PD where it closely correlates with dopaminergic striatal
innervation loss. Longitudinal studies should further explore the role of Neuromelanin-MRI
as an imaging biomarker of PD, especially for subjects at risk of developing the disease.
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INTRODUCTION
Parkinson’s disease (PD) is characterized by a loss of neuromelanin (NM) containing dopaminergic
neurons in the substantia nigra (SN), with a consequent reduction of dopamine concentration in
the putamen and caudate nucleus (Ehringer and Hornykiewicz, 1998), as well as iron deposition
throughout the SN. NM-containing neurons of the locus coeruleus (LC) also degenerate early in
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the disease process (Braak et al., 2003; Zarow et al., 2003). It has
been suggested that for every PD patient who presents withmotor
signs there may be 10 subclinical cases in the community (Golbe,
1993), as destruction of 60% of the NM-laden neurons in the SN
is expected before motor symptoms are manifest (Fearnley and
Lees, 1991). Identifying individuals in the preclinical stage of PD
is a fundamental step if we aim to reveal the pathophysiological
mechanisms of PD and consequently develop strategies to delay
disease onset.
To date, imaging measures of dopaminergic function, such
as Single-photon emission computed tomography (SPECT) with
[I-123] N-ω-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)
tropane (FP-CIT), represent a robust biomarkers for early PD
detection and assessing disease progression (Isaias et al., 2006,
2007; de la Fuente-Fernández et al., 2011). Such markers,
however, are mainly indicative of dopamine nerve terminal
activity which could be altered by compensatory mechanisms,
both endogenous and in response to treatment (Brooks
and Pavese, 2011; Stoessl et al., 2014) rather than SN cell
counts.
MRI techniques sensitive to NM (Sasaki et al., 2006; Kitao
et al., 2013; Miyoshi et al., 2013; Ogisu et al., 2013; Ohtsuka
et al., 2014) and iron (Graham et al., 2000; Martin et al.,
2008; Baudrexel et al., 2010; Schweser et al., 2011; Lotfipour
et al., 2012; Ulla et al., 2013) have been found to provide
information about SN degeneration with potential applications
as biomarkers of PD (Kashihara et al., 2011; Schwarz et al.,
2011; Matsuura et al., 2013; Miyoshi et al., 2013; Castellanos
et al., 2015). NM containing structures can be identified in
the NM-sensitive images (NM-MRI) as areas of hyperintensity.
A direct comparison between post-mortem NM-MRI and
neuropathological findings has shown that NM-MRI signal
intensity in the SN is closely associated with the quantity
of NM-containing neurons (Kitao et al., 2013), supporting
the link between NM-MRI hyperintensity with the presence
of NM.
Several histopathological, biochemical and in-vivo brain
imaging studies have shown an increase in total iron
concentration in the SN of PD patients (Dexter et al., 1987;
Graham et al., 2000; Zecca et al., 2001, 2004; Martin et al., 2008;
Baudrexel et al., 2010). Iron in tissue has an effect on the apparent
transverse relaxation rates (R2∗) that has been widely exploited
to characterize iron deposition in the SN (Baudrexel et al.,
2010; Ulla et al., 2013; Barbosa et al., 2015). The paramagnetic
properties of iron also influence the magnetic susceptibility
of the tissues (Schweser et al., 2011). This has recently been
demonstrated to allow quantification of tissue iron content based
on measurements of magnetic field inhomogeneity through
a technique called quantitative susceptibility mapping (QSM)
(Schweser et al., 2011; Langkammer et al., 2012; Lotfipour et al.,
2012) or visualized qualitatively as susceptibility weighted images
(Rossi et al., 2010; Schwarz et al., 2014; Langley et al., 2015; Reiter
et al., 2015).
This study aimed to investigate the correlations between MRI
markers (NM-MRI, R2∗, susceptibility) of the SN and LC of
PD patients and the corresponding nigro-striatal dopaminergic
innervation loss as measured by SPECT with FP-CIT.
SUBJECTS AND METHODS
Subjects
The study involved 18 subjects with PD (13males; median age: 64
years, range: 46–77 years) and 18 age-matched healthy controls
(HC group; 11 males; median age: 58 years, range: 47–77 years).
The diagnosis of PD was made according to the UK Parkinson
Disease Brain Bank criteria. The disease stage was determined
using the Hoehn and Yahr scale and the disease severity was
evaluated using the Unified Parkinson Disease Rating Scale
(UPDRS). UPDRS akinetic-rigid score (UPDRSAK) was derived
from the sum of UPDRS items 22 [head item excluded]-23-24-
25-26. We calculated this UPDRS sub-score as putaminal FP-
CIT binding was shown to exclusively correlate with the extent
of rigidity and hypokinesia (Isaias et al., 2007). None of the
patients showed signs indicative of atypical Parkinsonism over
a period of at least 3 years prior to the enrolment to this study.
All patients had a positive response to dopaminergic drugs.
Cognitive decline, depression as well as rapid eye movement
sleep behavior disorder were excluded for all subjects using
the Mini Mental State Examination (cut-off score of 28), the
Beck Depression Inventory-II (cut-off score of 6), and rapid eye
movement sleep behavior disorder screening questionnaire (cut-
off score of 5). Moreover, none of the patients reported having
suffered from any neurological or psychiatric disorders other
than idiopathic PD and none were taking, or stated to have ever
been treated with antipsychotics or antidepressants drugs. The
study was approved by the Local Ethics Committee (Comitato
EticoMilano Area B). MRI data were obtained prospectively with
written informed consent from all subjects. SPECT and clinical
data were obtained retrospectively from patients’ records.
SPECT with FP-CIT Acquisition and
Analysis
Brain SPECT was performed on all patients 3 h after intravenous
administration of 110–140 MBq of FP-CIT (DaTSCANTM, GE-
Healthcare, UK), as described in Isaias et al. (2008). A historic
group of 15 healthy volunteers, scanned on the same SPECT
camera (4 males; median age: 67 years, range: 44–74 years),
served as controls for SPECT measures (Isaias et al., 2007, 2008).
Binding values of dopamine reuptake transporters (DAT) of the
putamen and caudate nucleus were calculated on the basis of
VOIs defined by means of the Basal Ganglia Matching Tool
(Calvini et al., 2007). An asymmetry index was calculated for
putamen, and analogously for the caudate nucleus as Isaias et al.
(2008):
AIPutamen =
∣
∣
∣
∣
∣
(
PutamenIpsi − PutamenContra
)
(
PutamenIpsi + PutamenContra
) × 200
∣
∣
∣
∣
∣
where the subscript contra (contralateral) refers to the side
opposite to the clinically most impaired hemibody, and ipsi
(ipsilateral) refers to the most impaired hemibody. For HC
we adopted the conventional of referring to the right side as
ipsilateral.
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MR Image Acquisition
All subjects underwent MRI on a clinical 3T scanner (Achieva,
Philips Medical Systems, Best, the Netherlands) with a 32-
channel head coil. Conventional MRI scans were obtained to
exclude coexisting central nervous system disorders. NM-MRI
and multi-echo gradient echo scans were obtained for the
comparisons of NM and iron with the SPECT data.
The NM-MRI scan consisted of a T1-weighted fast spin echo
sequence with on-resonance magnetization transfer preparation
pulses (TE/TR 12/670 ms, echo train length 4, field of view 216
× 164mm2, acquisition/reconstruction resolution 0.5 × 0.6 ×
3.0mm3/0.5 × 0.5 × 3.0mm3, 12 slices, five averages), with
an acquisition time of approximately 7:40min (Figure 1). As in
previous studies (Nakane et al., 2008; Keren et al., 2009; Kitao
et al., 2013; Ogisu et al., 2013; Chen et al., 2014), magnetization
transfer preparation was used to improve the observable NM
contrast. The oblique axial slices of the NM-MRI scan were
defined perpendicular to the floor of the fourth ventricle, and
covered approximately from the posterior commissure to the
inferior pontine border.
Iron-sensitive imaging made use of a dual-echo, gradient echo
sequence (TE1/TE2/TR 9.2/23/30.44 ms, field of view 240 ×
240mm2, resolution 1 × 1 × 1mm3, 120 slices, flip angle 12◦)
with an acquisition time approximately 10min. Magnitude and
phase images were reconstructed from the gradient echo data for
each echo time. Again, the sections were in the oblique axial plane
perpendicular to the floor of the fourth ventricle.
Neuromelanin-Sensitive Image Analysis
As a measure of the presence of NM, the SN volume was
estimated from the NM-MRI images using the 3D Slicer software
package (version 4.3.1, http://www.slicer.org). In brief, similar to
previous studies (Chen et al., 2014; Langley et al., 2015), a reader,
blinded to the clinical status of the subjects, first defined circular
(4mm diameter) background regions of interest (ROIs) in the
FIGURE 1 | NM-MRI of the substantia nigra and locus coeruleus.
NM-MRI images at the levels of the substantia nigra (arrowhead) and the locus
coeruleus (arrow) of a 66-year-old healthy woman (A,C) and a 70-year-old
man with PD (B,D).
cerebral crus on the left and right sides (Figure 2A). This was
repeated for four consecutive slices, in which the SN was visible.
For each slice, a binary map was defined as the voxels in the
mesencephalic region with signal intensity greater than:
MNCC + 3× SDCC
where MNCC and SDCC are the mean and standard deviation
for the background ROI located in the cerebral crus on the
corresponding slice and side (Figure 2B). ROIs for the SN were
then defined on the binary map (Figure 2C).
The SN volume was calculated as the total number of voxels
in the segmented SN multiplied by the voxel dimensions. The
contrast-to-noise-ratio (CNR) between the SN and the cerebral
crus was calculated for each slice and side of the SN as:
CNRSN =
(MNSN − MNCC )
SDCC
whereMNSN andMNCC correspond to the mean signal intensity
of the SN and cerebral crus, respectively, and SDCC corresponds
to the standard deviation of the cerebral crus. The average CNR
of the SN across slices was then calculated for each side. The
asymmetry indices (AISN-Volume and AISN-CNR) were calculated
for the SN volume and the CNRSN in a way analogous to
that for SPECT measurements. Because the results of the above
procedure may depend on the placement of the cerebral crus
ROIs, the process of ROI drawing and calculation of the volume,
CNR and AI values for the SN was repeated four times, and
the average and standard deviation across measurements was
calculated.
As the cross-sectional area of the LC is near, or possibly below,
the resolution limit of our scans, we did not consider volumetry
of LC to be reliable. We instead limited our evaluation of the LC
to its contrast relative to surrounding tissue. For each side, the
location of the LC was taken to be the highest intensity voxel
adjacent to the fourth ventricle on that side (LCMAX) (Keren et al.,
2009). Once each LCMAX was located, the LC signal intensity was
taken to be the intensity of LCMAX and its four abutting voxels
in the image plane (Figure 3). This was repeated for each of
three consecutive 3mm-thick axial slices. Background reference
ROIs (circles with diameter 6mm) were placed in the pontine
tegmentum in the three slices in which the LC was identified.
This processing was carried out using a custom software routine
in Matlab (Mathworks Inc., Sherborn, MA, USA). The CNR
between the LC and the pontine tegmentum (TG) was calculated
in a way analogous to that for SN.
CNRLC =
(MNLC − MNTG )
SDTG
Lastly, to allow direct comparisons between CNRSN and CNRLC,
measurements were normalized to the corresponding median
value of the HC group to represent a % difference from normal
value (%CNRSN and %CNRLC, respectively).
Iron-Sensitive Image Analysis
Quantitative T2∗ maps were calculated from the magnitude
images at different echo times using the scanner manufacturer-
supplied software, and inverted to obtain R2∗ values. Phase and
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FIGURE 2 | Definition of region of interest (ROI) for the substantia nigra (SN) in the neuromelanin-MRI images involved (A) placing circular reference
ROIs in the cerebral crus, (B) creating binary map to identify high intensity voxels and (C) isolation of the voxel clusters corresponding to the SN.
FIGURE 3 | Definition of the region of interest (ROI) for the locus
coeruleus (LC) in the neuromelanin-MRI images involved identifying
the highest intensity voxel adjacent to the fourth ventricle (LCMAX),
which together with its four adjacent voxels were then used to
calculate LC signal intensity. The circular reference ROI in the pontine
tegmentum is also indicated.
magnitude images for the different echo times were processed
oﬄine to calculate quantitative maps of magnetic susceptibility
via the morphology-enabled dipole inversion method (MEDI-
Toolbox for Matlab, Cornell MRI Research Lab, New York, NY,
USA) (de Rochefort et al., 2010; Liu et al., 2011).
Bilateral SN ROIs were delineated manually by a blinder
researcher using the 3D Slicer software package. The SN ROIs
were drawn on the gradient echo magnitude images with the
longest echo-time (T2∗ weighted), and then applied to the R2∗
and susceptibility maps. The left and right SN were defined as
the hypointense bands between the red nucleus and cerebral
peduncle across six slices (Figure 4A). If the SN was visible in
more than six slices, then the six central slices where the SN
had the largest area were selected, starting either at the level of
the red nucleus showing the largest radius, or one slice lower to
minimize the probability of including the subthalamic nucleus.
Subsequently, the ROIs were used to sample the R2∗ (Figure 4B)
and susceptibility (Figure 4C) maps, and the mean values of R2∗
and susceptibility of the SN were calculated. The procedure was
repeated two times, and the average of the twomeasurements was
calculated.
Statistical Analysis
Statistical analysis were performed with the JMP statistical
package, (version 10.0, SAS Institute, Inc., Cary, NC, USA).
Gender difference between PD and HC groups was analyzed
using Pearson’s chi-squared test. Other differences between the
PD and HC groups were analyzed by means of Mann-Whitney
U test. The Spearman correlation coefficients (ρ) were calculated
to investigate statistical dependencies amongst MRI and SPECT
measures, demographic and clinical variables. The threshold level
of statistical significance was set at p< 0.05 (False Discovery Rate
corrected). A predictive analysis (least squares) between MRI
and SPECT measures were then performed. Receiver operating
characteristics analysis was performed to assess the diagnostic
accuracy of NM-MRI results. The 95% confidence intervals
for sensitivity and specificity were calculated according to the
Clopper-Pearson method. The intraclass correlation coefficient
was used to assess the intra-rater reliability.
RESULTS
Clinical Data
There were no significant gender or age differences between
the PD patients and the HC group recruited for the present
study. There was however, a significant difference in gender
between the PD group and the pre-existing HC group (used
here as controls for SPECT measures). Median age of the PD
patients at motor symptoms onset was 56 years (38–70 years).
Median disease duration was 6 years (3–15 years). Eight of the
PD patients had disease durations greater than the median value
of the PD group (11 years on average, range: 8–15 years); the
remaining 10 patients had referred motor signs for 6 years or less
(4 years on average; range: 3–6). All patients were at Hoehn and
Yahr stage 2. The median UPDRS-III (motor part) score was 14
(range: 5–25) in a “meds-off” phase (12 h L-Dopa withdrawal of
selegiline, rasagiline, amantadine, cabergoline, pergolide, and 72 h
discontinuation of prolonged duration formulations of dopamine
agonists). The median hemi-body UPDRSAK score was 6 (range:
1–8) and 2 (range: 0–4) for the more and less affected side
respectively. The average L-Dopa daily dose was 363 ± 152mg
and the average L-dopa equivalent daily dose was 502 ± 183 mg.
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SPECT with FP-CIT
When compared to a pre-existing group of HC, all PD patients
had significantly reduced striatal DAT binding values in both
putamen and caudate nucleus (Table 1). For both structures,
the reduction was greater on the side contralateral to the
most affected hemibody, as indicated by the asymmetry index
(AIPutamen and AICaudate). As expected, DAT binding values of
the Putamencontra negatively correlated with disease duration
(ρ = −0.51, p < 0.05), UPDRS-III and UPDRSAK score
(ρ = −0.46, p = 0.05 and ρ = −0.47, p < 0.05 respectively). It
is worth noting that striatal DAT binding did not differ between
male and female in our HC cohort.
Neuromelanin-Sensitive MRI
Areas of hyperintensity were reliably detected in the NM-MRI
images in positions corresponding to the locations of the SN
and LC (Figure 1), consistent with previous NM-MRI and post-
mortem studies (Sasaki et al., 2006; Keren et al., 2009, 2015;
Kitao et al., 2013). To account for intra-rater variability, every
measurement was performed four times, and the measurements
were averaged. The intraclass correlation coefficients were 0.88,
074, and 0.74 for the SN volume, the CNRSN , and the CNRLC,
respectively, which is an acceptable level of reproducibility. For
all NM-MRI measures, there were no significant differences
between sides (contra and ipsi) of the SN. In patients, the
mean SN volume-contra was lower than SN volume-ipsi, but the
difference did not reach statistical significance (p = 0.08). In
comparison to the HC group, the NM measures derived from
NM-MRI were significantly reduced in PD patients (Table 1).
SN volume-contra (but not SN volume-ipsi) was negatively
correlated with UPDRS-III (ρ=−0.61, p < 0.01) and UPDRSAK
(ρ=−0.63, p < 0.01).
CNRSN-contra was positively correlated with CNRLC-contra (ρ
= 0.56, p < 0.05), and all but four PD patients showed
greater %CNRLC-contra values than %CNRSN-contra. AISN-vol and
AISN-CNR were not significantly different between PD and HC
FIGURE 4 | Iron-sensitive imaging of the substantia nigra. The regions of interest for the substantia nigra were defined bilaterally for iron-sensitive imaging as the
hypointense band between the red nucleus and cerebral peduncle in the T2*-weighted images (A) and were then used to sample the R2* maps (B) and susceptibility
(C) maps, seen here for a 51-year-old man with PD.
TABLE 1 | Brain imaging findings in patients with PD and healthy subjects.
Patients with PD Healthy controls p-value
SPECT with FP-CIT Putamencontra 1.60±0.67 4.60±0.83 P < 0.001
Putamenipsi 2.06 ± 0.75 4.65 ± 0.83 P < 0.001
AIPutamen 28.09 ± 22.08 2.39 ± 1.75 P < 0.001
Caudatecontra 2.97 ± 1.02 4.92 ± 0.98 P < 0.001
Caudateipsi 3.28 ± 0.97 4.94 ± 0.96 P < 0.001
AICaudate 20.84 ± 26.71 3.22 ± 2.33 P < 0.001
NM-MRI SN volume-contra 236 ± 50mm
3 344 ± 51mm3 P < 0.001
SN volume-ipsi 283 ± 84mm
3 362 ± 60mm3 P < 0.01
AISN-volume 21.88 ± 15.32 13.82 ± 8.22 P > 0.05
CNRSN-contra 4.28 ± 0.41 4.91 ± 0.38 P < 0.001
CNRSN-ipsi 4.42 ± 0.45 4.83 ± 0.37 P < 0.01
AISN-CNR 8.59 ± 7.25 6.08 ± 3.72 P > 0.05
CNRLC-contra 3.54 ± 0.87 4.89 ± 0.61 P < 0.0001
CNRLC-ipsi 3.85 ± 0.96 5.07 ± 0.47 P < 0.001
Iron-sensitive MRI R2*
contra
41.17 ± 10.96 s−1 37.47 ± 5.16 s−1 P > 0.05
R2*
ipsi
43.30 ± 10.01 s−1 39.09 ± 5.74 s−1 P > 0.05
Susceptibilitycontra 0.16 ± 0.05 ppm 0.13 ± 0.03 ppm P > 0.05
Susceptibilityipsi 0.15 ± 0.05 ppm 0.13 ± 0.03 ppm P > 0.05
Data listed as mean± standard deviation. PT, putamen; CN, caudate nucleus; AI, asymmetry index; Vol, volume; SN, substantia nigra; CNR, contrast-to-noise-ratio; contra, contralateral
(to the side opposite to the clinically most impaired hemibody) and ipsi, ipsilateral. For HC we adopted the conventional of referring to the right side as ipsilateral.
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groups, and, for PD patients, they did not correlate with the
corresponding AIPutamen or AICaudate measurements. In fact, in
seven PD patients the CNRSN values were lower ipsilateral to
the worst affected hemibody and opposite to the putamen with
lowest DAT binding values. Despite this, significant positive
correlationwas also found between both SN volume(-contraand-ipsi)
(Figures 5A,B) and CNRSN(-contraand-ipsi) (Figures 5C,D) and the
corresponding DAT binding measurements of both the putamen
and the caudate nucleus amongst the patients. The CNRLC was
also significantly correlated with the corresponding DAT binding
measurements of putamen and caudate nucleus (Figures 5E,F).
Of all measurements, the best predictor of DAT reduction of
FIGURE 5 | Non parametric correlation analysis with linear regression between NM-MRI and SPECT measures in patients with PD. NM-MRI measures of
the substantia nigra (SN volume and CNRSN ) and locus coeruleus (CNRLC) were significantly correlated with DAT binding values of the putamen (A,C,E) and caudate
nucleus (B,D,F). The Spearman correlation coefficients (ρ) and the p-values are indicated in each figure. The filled circles correspond to the measurements in the
contralateral side, and the empty circles to the measurements in the ipsilateral side.
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both the putamen and caudate nucleus was the SN volume
(Figure 6).
The receiver operating characteristics analysis showed an area
under the curve of 0.94, and provided three relevant cut-off
values: (1) SN volume-contra = 325mm
3 with 83% diagnostic
accuracy, 100% sensitivity (95% confidence intervals: 81 to
100%), and 66.67% specificity (95% confidence intervals: 41 to
87%) in discriminating PD from HC (all PD subjects had lower
values); (2) SN volume-contra = 256mm
3 showing 83% diagnostic
accuracy, 66.67% sensitivity (95% confidence intervals: 41 to
87%) and 100% specificity (95% confidence intervals: 81 to
100%) (all HC had higher values); (3) SN volume-contra =
292mm3, with the highest diagnostic accuracy and a good
trade-off between sensitivity and specificity (accuracy = 86%,
sensitivity = 89% (95% confidence intervals: 65.29 to 98.62%),
and specificity = 83% (95% confidence intervals: 58.58 to
96.42%)).
Iron-Sensitive MRI
Quantitative maps of R2∗ and susceptibility showed a large
contrast between the SN and the surrounding brain tissue
(Figure 4), but we did not find significant differences in R2∗
and susceptibility values of the SN between the PD and HC
groups (Table 1). In PD patients, positive correlations with age
were seen for R2∗ipsi (ρ = 0.43, p < 0.01), Susceptibilityipsi (ρ
= 0.34, p < 0.05), and Susceptibilitycontra (ρ = 0.42, p < 0.05),
and with disease duration for R2∗ipsi (ρ = 0.52, p < 0.05),
Susceptibilityipsi (ρ = 0.66, p < 0.01) and Susceptibilitycontra
(ρ = 0.58, p < 0.05) (Figure 7). Neither R2∗ nor susceptibility
values correlated with any other demographic or clinical
parameter. Of the two correlated variables (i.e., age and disease
duration), disease duration proved, at a Stepwise regression
analysis, to independently correlate with both parameters (R2∗ipsi:
F-ratio = 4.22, p = 0.05; Susceptibilityipsi: F-ratio = 15.48,
p < 0.01), whereas the correlation with age was not statistically
significant. Lastly, no significant correlation was found when
FIGURE 6 | Prediction analysis of DAT binding values of the (A)
putamen and (B) caudate nucleus based on NM-MRI findings.
Prediction of DAT binding values was significant for both the putamen (p <
0.0001, R2 = 0.61, RMSE = 0.48, PRESS = 9.33) with SN volume being the
best predictor (p < 0.0001) (CNRSN leverage: p = 0.22, and CNRLC leverage:
p = 0.29), and the caudate nucleus (p < 0.0001, R2 = 0.50, RMSE = 0.73,
PRESS = 21.53) again with SN volume as the best predictor (p < 0.01)
(CNRSN leverage: p = 0.11, and CNRLC leverage p = 0.32). RMSE = Root
mean square error; PRESS = Predicted residual error sum of squares.
comparing R2∗ and susceptibility values with NM-MRI or
SPECT findings (Figure 8). The intraclass correlation coefficient
for the measurements were 0.91 and 0.90 for the R2∗ and
susceptibility, respectively.
DISCUSSION
PET and SPECT have been extensively employed to elucidate
the functional changes associated with PD and other
neurodegenerative disorders (Isaias et al., 2007, 2011; Brooks
and Pavese, 2011; Stoessl et al., 2011, 2014). To date, the imaging
measures of dopaminergic function by SPECT with FP-CIT
represent a robust biomarkers for early PD detection and
assessing disease progression. Although the deployment of
PET and SPECT scanners is becoming more common, their
availability is still limited. In addition, the expense, duration,
and invasive nature of radionuclide imaging limit its clinical
application, particularly for longitudinal assessment, large
cohorts of patients, and evaluation in non-confirmed cases
or subjects at risk to develop PD. MRI has been gaining
ground over the past decade as an attractive alternative to
radiotracer methods. MRI techniques have evolved to provide
novel information about the degenerative process in PD and
other movement disorders opening potential applications for
the differential diagnosis. Its non-invasive nature, diversity of
possible contrasts, lower cost, good availability, and in particular
the fact that MRI does not use ionizing radiation contribute to
its attractiveness.
Recently, the NM-MRI (Sasaki et al., 2006), has provided
notable contrast between NM-containing structures and
surrounding brain tissues with potential applications as
biomarker of PD. Several NM-MRI studies (Shibata et al., 2006;
Schwarz et al., 2011; García-Lorenzo et al., 2013; Miyoshi et al.,
2013; Ohtsuka et al., 2014; Castellanos et al., 2015) have shown
significant reductions in measures of NM-MRI contrast and
volume of the SN and LC in PD patients compared with healthy
controls, leading to the suggestion that the NM-related contrast
in MRI images reflects a loss of NM-containing neurons. In
fact, a direct comparison between post-mortem NM-MRI and
neuropathological findings (Kitao et al., 2013) has shown that
NM-MRI signal intensity in the SNc is closely associated with
the quantity of NM-containing neurons, supporting the link
between NM-MRI hyperintensity with the presence of NM, and
raising the prospect of NM-MRI being a potential biomarker
of PD.
In this study we investigated the correlations between
MRI markers of the SN and LC of PD patients and the
corresponding nigro-striatal dopaminergic innervation loss as
measured by SPECT with FP-CIT. Both of the examined NM-
MRI based measures of the SN (SN volume and CNRSN)
correlated significantly with dopaminergic striatal innervation
loss as measured by SPECT with FP-CIT (Figure 5) and SN
volume was highly correlated with striatal DAT binding values
(Figure 6). Also of relevance, NM-MRI measurements, as well
as SPECT findings, correlated with the severity of PD-related
motor signs. Our results support the ability of NM-MRI to
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FIGURE 7 | Non parametric correlation analysis with linear regression between the clinical data [age (A–D) and disease duration (E–H)] and the
iron-sensitive imaging measures [R2* (A,B,E,F) and susceptibility (C,D,G,H)] in -patients with PD. The Spearman correlation coefficients (ρ) and the p-values
are indicated in each figure. The filled circles correspond to the measurements in the contralateral side, and the empty circles to the measurements in the ipsilateral
side.
differentiate PD patients from healthy subjects as indicated in
previous reports (Sasaki et al., 2006; Ohtsuka et al., 2014). Also
in agreement with prior NM-MRI studies, PD patients showed
significant reductions in SN contrast and volume. In particular,
the cut-off of SN volume-contra = 292mm
3 obtained by
receiver operating characteristics analysis provided a diagnostic
accuracy of 86%, with good sensitivity (89%) and specificity
(83%).
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FIGURE 8 | Non parametric correlation analysis with linear regression between the SPECT measures in the putamen (A,C) and caudate nucleus (B,D)
and the iron-sensitive imaging measures (R2* and susceptibility) in patients with PD. No significant correlation was found when comparing R2* and
susceptibility values with the SPECT findings. The Spearman correlation coefficients (ρ) and the p-values are indicated in each figure. The filled circles correspond to
the measurements in the contralateral side, and the empty circles to the measurements in the ipsilateral side.
The discrepancy between asymmetry indexes (i.e., AIPutamen
and AISN-volume or AISN-CNR) was unexpected. In particular, the
asymmetry of DAT binding measurement at a striatal level in
PD patients was not mirrored by an asymmetry of NM-MRI
measurements. In light of the close correlation between post-
mortem NM-MRI and the quantity of NM-containing neurons
(Kitao et al., 2013), our findings for AISN-volume and AISN-CNR
may reflect the actual SN neuron loss, whereas the asymmetric
striatal DAT density seen with AIPutamen, and the consequent
asymmetry of clinical signs in PD patients, might be influenced
by pre-synaptic compensatory mechanisms.
Under the assumption that %CNRLC reflects neuron loss in
the LC area, the finding of greater %CNRLC in comparison
to the %CNRSN , would support the presence of an ascending
pathological process in PD patients (Braak et al., 2003). This was
indeed evident in 14 patients. However, the fact that four patients
did not show such a pattern suggests that it does not occur in
all PD patients. Notably, a reduced %CNRLC (averaged for both
hemispheres) from NM-MRI has recently been observed to be
specific to PD patients with concomitant rapid eye movement
sleep behavior disorder (García-Lorenzo et al., 2013). Thus, the
clinical characteristics and evolution of specific risk factors may
be determined by the changes at the LC, but require studies
suitable for the identification of such relationships. Despite these
interesting results, the difficulty in distinguishing the LC from
the sub-coeruleus region due to its position and size, and the
technical limitations of our NM-MRI (see below), we consider
the imaging and analysis methods for this structure to be
unsatisfactory.
The process of iron accumulation in SN of PD patients is
also not completely understood. Iron concentrations in dissected
SN pars compacta and pars reticulata measured with accurate
spectroscopic methods have shown that iron concentrations
in these regions increase with disease severity (Dexter et al.,
1987; Hirsch et al., 1991), and it has been proposed that
high iron content in the SN makes this region susceptible to
neurodegeneration (Zecca et al., 2004; Ward et al., 2014). In
the literature however, iron imaging results are mixed. Several
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reports have described an increase iron concentration in the
SN of PD patients (Graham et al., 2000; Martin et al., 2008;
Baudrexel et al., 2010), but equally, we and others did not find
significant differences in iron concentration between PD and
controls (Galazka-Friedman et al., 1996; Zecca et al., 2004; Ward
et al., 2014). We did however, find greater iron accumulation, as
indicated by R2∗ and susceptibility values, in PD patients with
longer disease duration, even accounting for age, and regardless
of their disease severity or dopaminergic drug doses. Moreover,
across the available MRI studies a rather large range of iron
concentration and confidence intervals has been reported both
in PD patients and controls (Martin et al., 2008; Lotfipour
et al., 2012; Ulla et al., 2013). These observations lead us to
suspect that subtle differences in patient characteristics and
measurement technique may be responsible for the inconsistency
of results obtained with iron imaging by MRI, such that better
standardization of technique is needed if the limitations of MRI
for accurate measurement of iron in brain tissue are to be
overcome and it is to have a role as a biomarker for PD (Martin
et al., 2008).
We did not attempt nigral subdivision into pars compacta
and pars reticulata, such as can be performed at higher magnetic
field (Lotfipour et al., 2012; Lehéricy et al., 2014). The region of
interest definitions we have used are however strongly tied to the
contrast in the images. Differences in location and morphology
of the SN are apparent in the ROIs defined for our NM-
and iron-sensitive MRI. Whereas areas of hyperintensity were
detected in the NM-MRI, the T2∗ weighted images showed
the SN as a hypointense band, rostral, and lateral to the
hyperintense area in the NM images. Langley et al. have recently
found NM and susceptibility weighted imaging contrasts to
be selectively sensitive to caudal and rostral compartments
of the SN respectively (Langley et al., 2015). They proposed
that the two histologically subregions of the SN, the SN pars
compacta and the SN pars reticulata, are delineated by NM-
MRI and susceptibility weighted imaging, respectively. NM-
MRI and susceptibility weighted imaging (or QSM as used
herein) are also complementary in their respective sensitivities
to neuronal death and iron deposition, such that investigation of
the degenerative processes in the SN is likely to benefit from their
combined use.
This study presented several limitations. First, the number
of patients in our study did not allow us to cover the full
spectrum of PD stages, and we selectively recruited patients
without any (non-dopaminergic) PD-related comorbidities (e.g.,
dementia, depression, postural instability or falls, rapid eye
movement sleep behavior disorder, etc.). This may limit our
scope for establishing clinical correlations, but was suited to the
study design, which was to directly compare MRI metrics of SN
pathology and its consequent striatal dopaminergic innervation
loss. Second, we obtained cut-off values for SN volume showing
high sensitivity and specificity in identifying PD patients, but
further studies testing these values in other groups of PD
patients and HC are required to validate their usability to
differentiate PD patients from HC. The estimates of SN volume,
and thus the cut-off points are dependent on the segmentation
method and imaging sequence characteristics. In this study,
we used a semiautomatic segmentation method based on the
approach previously described (Schwarz et al., 2011; Chen et al.,
2014). Although our intra-operator variability in segmentation
was reasonable, this and the inter-operator variability due to
background ROI positioning could be largely eliminated in future
studies through the use of completely automated segmentation
for quantification of SN and LC volumes using NM-MRI, as
recently suggested (Castellanos et al., 2015). Third, the NM-MRI
method applied here involved a clinically acceptable scan time
below 10min, but did not optimally resolve the LC for volumetric
assessment and even the SN volume measurements were subject
to partial volume effects. Further, the NM-MRI 2D multislice
scan yielded inhomogeneous signal intensities between slices
due to its sensitivity to radiofrequency field inhomogeneities,
and differing magnetization transfer weighting through cross-
talk effects. These necessitated a slice by slice approach to ROI
definition. A 3D acquisition, as described by Ogisu et al. (2013),
may allow more robust ROI definition. Last, there were also
some limitations regarding the iron-sensitive MRI technique. A
greater number of echoes may improve the R2∗ estimation and
the quality of the QSM results.
In conclusion, NM-MRI is a means of quantifying
SN pathology in PD patients that closely correlates with
dopaminergic striatal innervation loss. It may serve as an
imaging marker of PD, in particular regarding SN neuron loss,
although further longitudinal multi-imaging studies, possibly
involving subjects at risk of PD, are required.
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